Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway

2012 ◽  
Vol 14 (5) ◽  
pp. 353-362 ◽  
Author(s):  
Yuying Wei ◽  
Yuanjie Sun ◽  
Chaojun Song ◽  
Haitao Li ◽  
Yongming Li ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Major Histocompatibility Complex ◽  
Growth Factor ◽  
Dna Vaccine ◽  
Chorionic Gonadotropin ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Complex Class ◽  
Histocompatibility Complex ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document